Announcements Trials
Browse Landscape

Phase

Phase 2 23Phase 1 6Phase 4 3Phase 1/2 3Phase NA 1Phase EARLY_PHASE1 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Dermatologic 1Breast 1

Conditions

Turcot syndrome 1Melanoma 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × denileukin diftitox × Clear all
NCT05200559 2026-05-29

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

University of Pittsburgh

Phase 1/2 Active not recruiting
25 enrolled
Gynecologic

Turcot syndrome, Carcinoma, Ovarian Epithelial

NCT00945269 2022-11-15

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
3 enrolled
Dermatologic

Melanoma

NCT00425672 2018-12-05

ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment

University of Washington

Phase 1/2 Completed
15 enrolled 13 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡